8:00 am Registration & Networking Coffee
8:50 am Chair’s Opening Remarks
Assessing Current Limitations of Cell Engagers including Strategies to Mitigate Toxicities to Ensure Patient Safety
9:00 am XTENylated Protease Activated T Cell Engagers: XPATS – A Novel Format to Mitigate the On-target, Off-tumor Problem
9:30 am T Cell Engaging Antibody Circuits (TEAC): Focusing Immune Activation to the Cancer Cell Surface to Widen the Therapeutic Index
10:00 am TriTACs Are T Cell Engaging Drugs for Treatment of Solid Tumors
10:30 am Speed Networking & Morning Refreshments
12:00 pm Panel Discussion: Exploiting the High Protease Concentration in the Tumor Microenvironment to Reduce Toxicity
12:45 pm Networking Lunch
Improving the Therapeutic Window of Cell Engagers: Addressing Half-Life and Cytokine Release Syndrome
2:00 pm Discovering and Designing the Next Generation of T cell Engagers
2:30 pm Optimizing Therapeutic Index and Other Properties with Potency Reduction and Bivalent Target Engagement
3:00 pm CB307: A Novel T cell Enhancing Humabody Bispecific
3:00 pm
Synopsis
- T Cell Engagers with poor manufacturability can be improved using engineered coli SoluPro® cell linesT Cell Engagers with poor manufacturability can be improved using engineered coli SoluPro® cell lines
- A novel synthetic biology strategy using coli SoluPro® enables rapid and soluble expression of T Cell Engager proteins
- Precise engineering of protein expression conditions, folding solutions, and cytoplasmic conditions enable optimization of parameters for production of high titer, high quality therapeutics